These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 30856283)

  • 1. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
    Suenaga M; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Heinemann V; Lenz HJ
    Eur J Cancer; 2019 Jan; 107():100-114. PubMed ID: 30554073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.
    Barat A; Smeets D; Moran B; Zhang W; Cao S; Das S; Klinger R; Betge J; Murphy V; Bacon O; Kay EW; Van Grieken NCT; Verheul HMW; Gaiser T; Schulte N; Ebert MP; Fender B; Hennessy BT; McNamara DA; O'Connor D; Gallagher WM; Cremolini C; Loupakis F; Parikh A; Mancao C; Ylstra B; Lambrechts D; Lenz HJ; Byrne AT; Prehn JHM
    Sci Rep; 2020 Jun; 10(1):9778. PubMed ID: 32555399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
    Summers MG; Maughan TS; Kaplan R; Law PJ; Houlston RS; Escott-Price V; Cheadle JP
    Eur J Cancer; 2020 Jan; 124():56-63. PubMed ID: 31734605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer.
    Wang D; Zhang X; Zhang Y; Wu Y; Guan X; Zhu W; Wang M; Qi C; Shen B
    Onco Targets Ther; 2018; 11():8083-8088. PubMed ID: 30519050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of PTGER4 and PRKAA1 genetic polymorphisms with gastric cancer.
    Yu S; Tu R; Chen Z; Song J; Li P; Hu F; Yuan G; Zhang R; Li Y
    BMC Med Genomics; 2023 Sep; 16(1):209. PubMed ID: 37670284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 7. Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action.
    Zhan L; Su F; Li Q; Wen Y; Wei F; He Z; Chen X; Yin X; Wang J; Cai Y; Gong Y; Chen Y; Ma X; Zeng J
    Front Pharmacol; 2023; 14():1257450. PubMed ID: 37693915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular mechanism for inhibiting the growth of nasopharyngeal carcinoma cells using polymethoxyflavonoids purified from pericarp of
    Yang W; Liang Y; Liu Y; Chen B; Wang K; Chen X; Yu Z; Yang D; Cai Y; Zheng G
    Front Pharmacol; 2023; 14():1096001. PubMed ID: 37180721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials.
    Wang J; Millstein J; Yang Y; Stintzing S; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Mancao C; Cremolini C; Liu T; Heinemann V; Falcone A; Shen L; Lenz HJ
    EClinicalMedicine; 2023 Mar; 57():101827. PubMed ID: 36816347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
    Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
    Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
    Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
    Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Leal F; Ferreira FP; Sasse AD
    Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
    Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
    Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.